Expression and clinical significance of UTP14a and c-myc in breast cancer tissues

Published on Apr. 28, 2025Total Views: 11 times Total Downloads: 3 times Download Mobile

Author: MENG Xiangyu ^1, ²  ZHANG Mao ³ LIU Pengcheng ² JIN Zhicheng ² TANG Qi ⁴

Affiliation: 1. Baotou Medical College, Inner Mongolia University of Science & Technology, Baotou 014040, Inner Mongolia Autonomous Region, China 2. Department of Thyroid and Breast Surgery, Baotou City Central Hospital, Baotou 014040, Inner Mongolia Autonomous Region, China 3. Department of Head and Neck Surgery, Baotou Cancer Hospital, Baotou 014030, Inner Mongolia Autonomous Region, China 4. Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Baotou Medical College, Baotou 014040, Inner Mongolia Autonomous Region, China

Keywords: UTP14a c-myc Breast cancer Bioinformatics Immunohistochemistry

DOI: 10.12173/j.issn.1004-4337.202411027

Reference: Meng XY, Zhang M, Liu PC, Jin ZC, Tang Q. Expression and clinical significance of UTP14a and c-myc in breast cancer tissues[J]. Journal of Mathematical Medicine, 2025, 38(4): 267-275. DOI: 10.12173/j.issn.1004-4337.202411027[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To explore the differential expression, diagnostic and prognostic value of c-myc and UTP14a in breast cancer tissues and adjacent tissues through bioinformatics analysis and immunohistochemical experiments.

Methods UTP14a and c-myc gene expression and clinical information data of cancer patients were obtained from The Cancer Genome Atlas (TCGA) database, and survival expression was analyzed. Immunohistochemical staining of UTP14a and c-myc was performed on cancer tissue samples from 92 breast cancer patients. The relationship between the expression levels of UTP14a and c-myc in different subgroups and prognosis was analyzed using χ² test and Spearman correlation coefficient.

Results The results of receiver operating characteristic (ROC) curve analysis showed that the area under curve (AUC) values of UTP14a at 1 year, 3 and 5 years were 0.559 (95%CI: 0.445-0.672), 0.542 (95%CI: 0.480-0.605) and 0.545 (95%CI: 0.488-0.603), respectively. The results of KM survival curve analysis showed that there was no significant difference in survival between UTP14a high risk and low risk groups (P=0.083). The AUC values of c-myc at 1 year, 3 and 5 years were 0.629 (95%CI: 0.550-0.708), 0.530 (95%CI: 0.460-0.600) and 0.514 (95% CI: 0.438-0.590), respectively. The results of KM survival curve analysis showed that there was no significant difference in survival between c-myc high risk and low risk groups (P=0.149). The results of immunohistochemical experiments showed that UTP14a and c-myc were mainly expressed in the nucleus and cytoplasm of cancer cells, and the positive expression rates of UTP14a and c-myc in tumor tissues were higher than those in normal tissues (P<0.05). The expression of UTP14a in breast cancer tissues was significantly correlated with the patient's age, histological grading, and the rate of metastasis to axillary lymph nodes (P<0.05). The expression of c-myc in breast cancer tissues was significantly correlated with histological grading, the rate of metastasis to axillary lymph nodes, nerve invasion ratio and positive expression of estrogen receptor (ER) (P<0.05). There was positive correlation between the expression of c-myc antibody and UTP14a antibody (P<0.05).

Conclusion The combined detection of UTP14a and c-myc may provide important reference for the treatment of breast cancer patients and help clinicians to better individualize treatment. The results of this study need to be validated in a larger cohort in the future to support its application in clinical practice.

Full-text

Please download the PDF version to read the full text: download

References

1.Xiong X, Zheng LW, Ding Y, et al. Breast cancer: pathogenesis and treatments[J]. Signal Transduct Target Ther, 2025, 10(1): 49. DOI: 10.1038/s41392-024-02108-4.

2.Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040[J]. Breast, 2022, 66: 15-23. DOI: 10.1016/j.breast.2022.08.010.

3.Pan X, Chen S, Chen X, et al. UTP14A, DKC1, DDX10, PinX1, and ESF1 modulate cardiac angiogenesis leading to obesity-induced cardiac injury[J]. J Diabetes Res, 2022, 2022: 2923291. DOI: 10.1155/2022/2923291.

4.Scherl A, Couté Y, DéonC, et al. Functional proteomic analysis of human nucleolus[J]. Mol Biol Cell, 2002, 13(11): 4100-4109. DOI: 10.1091/mbc.e02-05-0271.

5.Rohozinski J, Lamb DJ, Bishop CE. UTP14c is a recently acquired retrogene associated with spermatogenesis and fertility in man[J]. Biol Reprod, 2006, 74(4): 644-651. DOI: 10.1095/biolreprod.105.046698.

6.Gao FY, Li XT, Xu K, et al. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment[J]. Cell Commun Signal, 2023, 21(1): 28. DOI: 10.1186/s12964-023-01043-1.

7.Thompson EB. The many roles of c-Myc in apoptosis[J]. Annu Rev Physiol, 1998, 60: 575-600. DOI: 10.1146/annurev.physiol. 60.1.575.

8.Einstein JM, Perelis M, Chaim IA, et al. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer[J]. Mol Cell, 2021, 81(15): 3048-3064. DOI: 10.1016/j.molcel. 2021.06.014.

9.Zhang J, Ren P, Xu D, et al. Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc[J]. Cancer Lett, 2019, 440-441: 106-115. DOI: 10.1016/j.canlet.2018.10.010.

10.Alles MC, Gardiner-Garden M, Nott DJ, et al. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup[J]. PLoS One, 2009, 4(3): e4710. DOI: 10.1371/journal.pone.0004710.

11.Tang M, O'Grady S, Crown J, et al. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975[J]. Breast Cancer Res Treat, 2022, 195(2): 105-115. DOI: 10.1007/s10549-022-06673-6.

12.Zhang JY, Xu D, Liu ZZ, et al. Human U three protein 14a expression is increased in hepatocellular carcinoma and associated with poor prognosis[J]. Chin Med J (Engl), 2017, 130(4): 470-476. DOI: 10.4103/0366-6999.199839.

13.曾剑锋, 邱成志, 周志平, 等. c-myc蛋白在三阴性乳腺癌组织表达及其与术后复发转移关系研究[J]. 中国实用外科杂志, 2014, 34(4): 339-343. [Zeng JF, Qiu CZ, Zhou ZP, et al. Expression of c-myc in triple negative breast cancer and its relationship with recurrence and metastasis[J]. Chinese Journal of Practical Surgery, 2014, 34(4): 339-343.] https://www.cqvip.com/doc/journal/941236604?sign=58ef029c06da69463fb4afbacd0c2bfab7c209b4cbf84b8c5df75293e4626101&expireTime=1744792013108&resourceId=941236604

14.杨建国, 杨红利, 王乐. 缺氧诱导因子1α联合c-myc预测三阴性乳腺癌病人术后生存[J]. 临床外科杂志, 2022, 30(12): 1172-1175. [Yang JG, Yang HL, Wang L, et al. Prediction of postoperative survival of triple-negative breast cancer combined with expression of HIF-1α and c-myc[J]. Journal of Clinical Surgery, 2022, 30(12): 1172-1175.] DOI: 10.3969/j.issn.1005-6483.2022.12.021.

15.Shiu RP, Watson PH, Dubik D. c-myc oncogene expression in estrogen-dependent and -independent breast cancer[J]. Clin Chem, 1993, 39(2): 353-355. https://pubmed.ncbi.nlm.nih.gov/8432027/

16.Guarducci C, Nardone A, Russo D, et al. Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor-positive breast cancer[J]. Clin Cancer Res, 2024, 30(9): 1889-1905. DOI: 10.1158/1078-0432.CCR-23-2975.

17.张莹, 范静婧, 吴中语, 等. c-Myc调控葡萄糖转运蛋白4激活酪氨酸激酶/信号转导与转录激活因子促进三阴性乳腺癌机制研究[J]. 中华实验外科杂志, 2024, 41(4): 674-678. [Zhang Y, Fan JJ, Wu ZY, et al. c-Myc regulates glucose transporters 4 to activate the janus kinase/signal transducer and activators of transcription to promote triple negative breast cancer[J]. Chinese Journal of Experimental Surgery, 2024, 41(4): 674-678.] DOI: 10.3760/cma.j.cn421213-20230711-01250.

18.Yang L, Wang M, Wang Y, et al. LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance[J]. Oncogene, 2024, 43(17): 1249-1262. DOI: 10.1038/s41388-024-02972-y.